1. Home
  2. SRTA vs AUTL Comparison

SRTA vs AUTL Comparison

Compare SRTA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SRTA

Strata Critical Medical Inc.

HOLD

Current Price

$5.53

Market Cap

425.3M

Sector

N/A

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$1.58

Market Cap

407.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRTA
AUTL
Founded
2014
2014
Country
United States
United Kingdom
Employees
601
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
425.3M
407.2M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
SRTA
AUTL
Price
$5.53
$1.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$7.81
$8.50
AVG Volume (30 Days)
741.8K
1.3M
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,120,000.00
Revenue This Year
$39.27
$80.32
Revenue Next Year
$8.52
$53.96
P/E Ratio
$9.88
N/A
Revenue Growth
N/A
496.00
52 Week Low
$3.85
$1.18
52 Week High
$6.02
$2.70

Technical Indicators

Market Signals
Indicator
SRTA
AUTL
Relative Strength Index (RSI) 69.70 54.85
Support Level $4.08 $1.34
Resistance Level $5.99 $1.69
Average True Range (ATR) 0.30 0.09
MACD 0.06 0.01
Stochastic Oscillator 93.89 54.17

Price Performance

Historical Comparison
SRTA
AUTL

About SRTA Strata Critical Medical Inc.

Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: